| Literature DB >> 34822175 |
Patrick W Mellors1, Taxiarchis Kourelis2,3, Ronald S Go2, Eli Muchtar2, Morie A Gertz2, Shaji K Kumar2, Francis K Buadi2, Prashant Kapoor2, Martha Q Lacy2, David Dingli2, Yi Hwa2, Amie Fonder2, Miriam Hobbs2, Suzanne Hayman2, Rahma Warsame2, Nelson R Leung2, Yi Lin2, Wilson Gonsalves2, Mustaqeem Siddiqui2, Robert A Kyle2, S Vincent Rajkumar2, Angela Dispenzieri2,3.
Abstract
Thromboses are prevalent in POEMS syndrome, but few risk factors for POEMS-associated thrombosis have been identified. The objective of this study is to identify novel risk factors for POEMS-associated thrombosis. In this retrospective cohort of 230 POEMS patients, 27% developed thrombosis. Arterial events were slightly more common than venous. Stroke accounted for 26% of all thromboses and 53% of arterial events. There were differences in baseline features between the thrombosis group and the no thrombosis group, and these were driven by patients with arterial thrombosis. Risk factors for arterial thrombosis included thrombocytosis, elevated hemoglobin/hematocrit, extravascular volume overload, and splenomegaly. Hyperprolactinemia appeared to be a risk factor for venous thrombosis. The risk of thrombosis was most striking among men with elevated hemoglobin (32% vs. 5%, p < .001) and hematocrit (42% vs. 5%, p < .001) compared to men without. Most thromboses occurred prior to POEMS directed therapy, and most that occurred during therapy happened within 3 months of diagnosis. Twenty-one percent of patients with thrombosis had recurrence. In recognition of high overall rates of thrombosis in this population, all patients with POEMS syndrome should receive prophylactic antiplatelet therapy, and clinicians should consider anticoagulation in patients with risk factors for POEMS-associated thrombosis.Entities:
Mesh:
Year: 2021 PMID: 34822175 PMCID: PMC8738145 DOI: 10.1002/ajh.26422
Source DB: PubMed Journal: Am J Hematol ISSN: 0361-8609 Impact factor: 10.047